Article info

Download PDFPDF
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
  1. Correspondence to:
    Dr Michael H Schiff
    Clinical Research, Denver Arthritis Clinic, 200 Spruce Street, Suite 100, Denver, CO 80230, USA; crendon{at}denverarthritisclinic.com
View Full Text

Citation

Schiff MH, Burmester GR, Kent JD, et al
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

Publication history

  • Accepted January 2, 2006
  • First published January 26, 2006.
Online issue publication 
June 12, 2006

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.